Posts Tagged ‘AstraZeneca’

Drugged to Death: Soldiers returning from war are being given deadly cocktails of psychiatric drugs

Tuesday, March 9th, 2010

AlterNet
By Martha Rosenberg
March 9, 2010

Sgt. Eric Layne’s death was not pretty.

A few months after starting a drug regimen combining the antidepressant Paxil, the mood stabilizer Klonopin and a controversial anti-psychotic drug manufactured by pharmaceutical giant AstraZeneca, Seroquel, the Iraq war veteran was “suffering from incontinence, severe depression [and] continuous headaches,” according to his widow, Janette Layne.

Soon he had tremors. ” … [H]is breathing was labored [and] he had developed sleep apnea,” Layne said.

Janette Layne, who served in the National Guard during Operation Iraqi Freedom along with her husband, told the story of his decline last year, at official FDA hearings on new approvals for Seroquel. On the last day of his life, she testified, Eric stayed in the bathroom nearly all night battling acute urinary retention (an inability to urinate). He died while his family slept.

Sgt. Layne had just returned from a seven-week inpatient program at the VA Medical Center in Cincinnati where he was being treated for post-traumatic stress disorder (PTSD). A video shot during that time, played by his wife at the FDA hearings, shows a dangerously sedated figure barely able to talk.

Sgt. Layne was not the first veteran to die after being prescribed medical cocktails including Seroquel for PTSD.

Read entire article:  http://www.alternet.org/world/145892/are_veterans_being_given_deadly_cocktails_to_treat_ptsd

« Return to news items


  • Share/Bookmark

Drug Giant AstraZeneca to drop psychiatric drug research for schizophrenia, bipolar, depression & anxiety drugs

Tuesday, March 2nd, 2010

Reuters
By Ben Hirschler
March 2, 2010

AstraZeneca (AZN.L) is to stop researching some disease areas that form the backbone of its current business — including schizophrenia and acid reflux — in a drive to focus R&D efforts and cut costs.

The Anglo-Swedish drugmaker, which faces one of the sector’s worst “cliffs” of expiring drug patents, told its staff on Tuesday it would cease discovery in 10 of its current disease areas, or around one quarter of the total.

A wide-ranging overhaul had been expected since the group said in January it was cutting a further 8,000 staff, or some 12 percent of the workforce, including a net 1,800 in research. But it is only now that staff know where the axe will fall.

AstraZeneca is not alone in taking the knife to previously sacrosanct R&D, though its cuts are particularly deep. Pfizer (PFE.N) and GlaxoSmithKline (GSK.L) are also ditching drug discovery work that does not pay its way. [ID:nLDE61408I]

Read entire article:  http://www.reuters.com/article/idUSLDE62019Q20100302?type=marketsNews

« Return to news items


  • Share/Bookmark

Drug maker AstraZeneca facing 26,000 lawsuits over its antipsychotic drug Seroquel causing diabetes

Wednesday, February 3rd, 2010

Bloomberg.com
By Jef Feeley and Margaret Cronin Fisk
February 3, 2010

AstraZeneca Plc is facing as many as 26,000 lawsuits over its antipsychotic drug Seroquel as the drugmaker prepares for its first jury trial over claims the medicine causes diabetes, according to court filings.

Attorneys for AstraZeneca, the U.K.’s second-largest drugmaker, met with plaintiffs’ lawyers in court-ordered mediation sessions last month to discuss a possible settlement of the Seroquel cases, according to court filings. Consumers’ lawyers said they had about 26,000 cases in their inventories, Stephen Saltzburg, a George Washington University Law School professor who served as mediator, said in the filing.

“I wish there were a magic wand that could be waived to settle all Seroquel cases instantly,” Saltzburg said in the filing. “Such wand does not exist.”

AstraZeneca’s stock fell last week after the drugmaker’s sales forecast and stock-buyback plan disappointed some analysts and fourth-quarter profit missed estimates. The company plans to buy back as much as $1 billion of shares this year, officials said Jan. 28.

The company said in a U.S. Securities and Exchange Commission filing last week it faces more than 25,000 claims that Seroquel caused diabetes.

Read entire article:  http://www.bloomberg.com/apps/news?pid=20601087&sid=a6MfYbj9JtRc&pos=7

That’s a 65 percent increase in cases over the number the company reported in a January 2009 regulatory filing. Many of the suits also claim AstraZeneca promoted Seroquel, approved for schizophrenic and bipolar patients, for unapproved uses.

« Return to news items


  • Share/Bookmark

New allegations of suppressed drug data surface as thousands sue over antipsychotic drug causing weight gain/diabetes

Friday, January 29th, 2010

BBC News
January 26, 2010

The marketing team sued over a drug’s alleged side effects tried to suppress key data, an ex-employee has claimed.

Seroquel’s former UK medical adviser told the BBC he was pressured to approve promotional material which said weight gain was not an issue.

Maker AstraZeneca, which faces fresh legal action next month, said it took concerns about its conduct seriously.

In the same programme, the British Medical Journal editor urged that the medicine licensing system be reviewed.

Dr Fiona Godlee said industry should no longer provide the evaluations of its own drugs which the licensing body considered.

‘Job threat’

Thousands of patients are suing AstraZeneca in US courts, claiming the anti-psychotic drug Seroquel caused weight gain and diabetes.

The patients allege Seroquel, its second biggest selling drug worth $4.5bn (£2.7bn) a year, was marketed without adequate warning about possible side effects such as massive weight gain and the development of diabetes. However, this is denied by the company.

Read entire article:  http://news.bbc.co.uk/2/hi/health/8478924.stm

« Return to news items


  • Share/Bookmark

Big Pharma paid $500,000 to Chicago psychiatrist who used children as guinea pigs

Sunday, December 20th, 2009

E. Huff
NaturalNews.com
December 18, 2009

A federal lawsuit has been filed against pharmaceutical giant AstraZeneca for its role in paying Chicago psychiatrist Dr. Michael Reinstein nearly $500,000 over the course of a decade to conduct research and to promote its anti-psychotic drug, Seroquel. Reinstein is being accused of wrongfully preying on thousands of mentally-ill patients in order to rake in profits for AstraZeneca.

Reinstein has a long history of working with AstraZeneca, receiving regular payments for speeches he would make across the country promoting the drug. AstraZeneca was also paying a for-profit research company, Uptown Research Institute, who in turn was paying Reinstein consulting fees for his services.

Cited in the lawsuit was the fact that Reinstein would continually prescribe roughly double the amount of drugs other psychiatrists would prescribe for the same conditions. When patients would report their pain and suffering due to the tremendous side effects of such drugs and their abnormally high dosages, Reinstein would largely ignore their concerns.

Read entire article: http://www.naturalnews.com/027765_psychiatrists_Seroquel.html

« Return to news items


  • Share/Bookmark

That British Drug Maker Glaxo’s $1 Billion Paxil Settlements Were Disclosed by Press – Not Drug Maker – Is Cause for Concern

Tuesday, December 15th, 2009

Jim Edwards
BNET
December 15, 2009

British drug company GlaxoSmithKline (GSK) has paid $1 billion to settle lawsuits related to Paxil. The fact that it was disclosed by Bloomberg and not the company itself illustrates how lousy financial disclosure rules are in Europe and why drug companies based there cannot be trusted to tell the truth about what is going on with their litigation liabilities and, by extension, the safety of their drugs.

Bloomberg got the $1 billion number by piecing together litigation records, analysts’ reports and GSK’s own partial statements on the issue. But compare the Paxil situation with those faced by Eli Lilly (LLY) and AstraZeneca (AZN). Both companies have been engaged in litigation that has cost them billions (over the antipsychotics Zyprexa and Seroquel, respectively). And both companies have disclosed the full legal bill attached to those suits. (It’s more than $3.3 billion for Lilly and $1.1 billion for AZ.

Those numbers were disclosed in both companies’ earnings reports. Interestingly, Lilly disclosed them because it was required to report anything “material” by the SEC — it’s an American company and that’s the law. Fines and prosecutions await American firms that fail to report bad news.

Read entire article: http://industry.bnet.com/pharma/10005807/gsks-1b-paxil-problem-highlights-murky-disclosures-from-euro-drug-companies/

« Return to news items


  • Share/Bookmark

US Kids Represent Psychiatric Drug Goldmine

Monday, December 14th, 2009

Truthout
Evelyn Pringle
December 12, 2009

Prescriptions for psychiatric drugs increased 50 percent with children in the US, and 73 percent among adults, from 1996 to 2006, according to a study in the May/June 2009 issue of the journal Health Affairs. Another study in the same issue of Health Affairs found spending for mental health care grew more than 30 percent over the same ten-year period, with almost all of the increase due to psychiatric drug costs.

On April 22, 2009, the US Agency for Healthcare Research and Quality reported that in 2006 more money was spent on treating mental disorders in children aged 0 to 17 than for any other medical condition, with a total of $8.9 billion. By comparison, the cost of treating trauma-related disorders, including fractures, sprains, burns, and other physical injuries, was only $6.1 billion.

In 2008, psychiatric drug makers had overall sales in the US of $14.6 billion from antipsychotics, $9.6 billion off antidepressants, $11.3 billion from antiseizure drugs and $4.8 billion in sales of ADHD drugs, for a grand total of $40.3 billion.

The path to child drugging in the US started with providing adolescents with stimulants for ADHD in the early 80s. That was followed by Prozac in the late 80s, and in the mid-90s drug companies started claiming that ADHD kids really had bipolar disorder, coinciding with the marketing of epilepsy drugs as “mood stablizers” and the arrival of the new atypical antipsychotics.

Read entire article: http://www.truthout.org/1213091

« Return to news items


  • Share/Bookmark

Drugmaker pays psychiatrist nearly $500,000 to promote antipsychotic drug Seroquel despite misgivings about his research

Friday, November 13th, 2009

Christina Jewett, ProPublica
SamRoe, Chicago Tribune
November 11, 2009

Executives inside pharmaceutical giant AstraZeneca faced a high-stakes dilemma.

On one hand, Chicago psychiatrist Dr. Michael Reinstein was bringing the company a small fortune in sales and was conducting research that made one of its most promising drugs look spectacular.

On the other, some worried that his research findings might be too good to be true.

As Reinstein grew irritated with what he perceived as the company’s slights, a top executive outlined the scenario in an e-mail to colleagues.

“If he is in fact worth half a billion dollars to (AstraZeneca),” the company’s U.S. sales chief wrote in 2001, “we need to put him in a different category.” To avoid scaring Reinstein away, he said, the firm should answer “his every query and satisfy any of his quirky behaviors.”

Putting aside its concerns, AstraZeneca would continue its relationship with Reinstein, paying him $490,000 over a decade to travel the nation promoting its best-selling antipsychotic drug, Seroquel. In return, Reinstein provided the company a vast customer base: thousands of mentally ill residents in Chicago-area nursing homes.

Read entire article: http://www.chicagotribune.com/health/chi-drugs-seroquel-reinsteinnov11,0,6067737.story

« Return to news items


  • Share/Bookmark

Psych journal “looks into” whether psychiatrist who endorsed antidepressants for preschoolers was getting Pharma $$

Thursday, September 10th, 2009

Jim Edwards
bnet.com
September 10, 2009

The journal Archives of General Psychiatry will “look into” whether an author who recommended antidepressants for preschoolers failed to disclose her financial ties to Johnson & Johnson, AstraZeneca and, companies which make such drugs, according to Philip Dawdy of Furious Seasons.

Dr. Joan Luby,  a professor of child psychiatry at the Washington University School of Medicine in St. Louis, has authored several papers asserting that children as young as three years old can suffer from depression and bipolar disorder, and that treatment with antidepressants and antipsychotics may be appropriate. In a recent paper of the AGP, she wrote:

Preschool depression, similar to childhood depression, is not a developmentally transient syndrome but rather shows chronicity and/or recurrence.

She did not disclose any ties to industry. However, Luby has past ties to J&J’s Janssen unit, AZ and Shire (makers of Risperdal, Seroquel and Adderall XR, respectively).

Read entire article: http://industry.bnet.com/pharma/10004189/agp-to-probe-undisclosed-industry-ties-of-doc-who-recommends-antidepressants-for-3-year-olds/

« Return to news items


  • Share/Bookmark

No Surprise: Psychiatrist pushing “Depression” testing for 3-yr-olds connected to three drug companies

Monday, August 17th, 2009

Martha Rosenberg
The Epoch Times
August 17, 2009

Try to access the Web site of the Archives of General Psychiatry, and you may have to abide an ad for the antidepressant Pristiq before you can enter. (JAMA and its Archives Journals “do not endorse the advertised product,” you’ll be assured.)

But look for a pharma affiliation for the author of the article “Preschool Depression,” Joan L. Luby, M.D., in the August issue, and you’ll be told no “financial disclosure” was reported. Not that “Dr. Luby has received grant/research support from Janssen, has given occasional talks sponsored by AstraZeneca, and has served as a consultant for Shire Pharmaceutical,” as a 2006 article in Journal of the American Academy of Child and Adolescent Psychiatry says.

Even though the pharmaceutical industry has 27 million Americans—10 percent of the population—on antidepressants, thanks to direct to consumer advertising, it is looking for depression in preschoolers. And guess what? It’s finding it!

Read entire article: http://www.theepochtimes.com/n2/content/view/21114/

« Return to news items


  • Share/Bookmark